Show simple item record

dc.contributor.authorArifoglu, Alptekin
dc.contributor.authorSahin, Bilgehan
dc.contributor.authorATALAR, Banu
dc.contributor.authorKaytan Saglam, Esra
dc.contributor.authorAkgun, Zuleyha
dc.contributor.authorAbacioglu, Ufuk
dc.contributor.authorÖZYAR, Enis
dc.contributor.authorYaprak, Gokhan
dc.contributor.authorOzseker Isik, Naciye
dc.contributor.authorGuney, Yildiz
dc.contributor.authorCaglar, Hale Basak
dc.contributor.authorKaraman, Sule
dc.contributor.authorIgdem, Sefik
dc.contributor.authorSelek, Ugur
dc.contributor.authorBerber, Tanju
dc.contributor.authorOner Dincbas, Fazilet
dc.contributor.authorSengoz, Meric
dc.contributor.authorYÜCEL, Serap
dc.contributor.authorDEMİRAL, AYŞE NUR
dc.contributor.authorAKYÜREK, SERAP
dc.date.accessioned2021-03-02T17:30:14Z
dc.date.available2021-03-02T17:30:14Z
dc.identifier.citationSahin B., ATALAR B., Kaytan Saglam E., Akgun Z., Abacioglu U., Arifoglu A., ÖZYAR E., Yaprak G., Ozseker Isik N., Guney Y., et al., "Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study", CLINICAL RESPIRATORY JOURNAL, 2020
dc.identifier.issn1752-6981
dc.identifier.otherav_84956577-85ce-46fa-952c-e1965cb383d4
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3874
dc.identifier.urihttps://doi.org/10.1111/crj.13240
dc.description.abstractObjective We identified factors influencing outcomes in patients with medically inoperable early stage lung cancer (MIESLC) treated with stereotactic ablative radiation therapy (SABR) at 14 centers in Turkey. Materials and Methods We retrospectively analyzed 431 patients with stage I-II MIESLC treated with SABR from 2009 through 2017. Age; sex; performance score; imaging technique; tumor histology and size; disease stage radiation dose, fraction and biologically effective dose with an alpha/beta ratio of 10 (BED10); tumor location and treatment center were evaluated for associations with overall survival (OS), local control (LC) and toxicity. Results Median follow-up time was 27 months (range 1-115); median SABR dose was 54 Gy (range 30-70) given in a median three fractions (range 1-10); median BED(10)was 151 Gy (range 48-180). Tumors were peripheral in 285 patients (66.1%), central in 69 (16%) and 100 Gy (P = .011), adenocarcinoma (P = .025) and complete response on first evaluation (P = .007) predicted favorable LC. BED10> 120 Gy (hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.1-3.2,P = .019) and tumor size ( 120 Gy was needed for better LC and OS for large, non-adenocarcinoma tumors.
dc.language.isoeng
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectSOLUNUM SİSTEMİ
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titlePrognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study
dc.typeMakale
dc.relation.journalCLINICAL RESPIRATORY JOURNAL
dc.contributor.departmentAcıbadem Mehmet Ali Aydınlar Üniversitesi , ,
dc.contributor.firstauthorID2285530


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record